SE9900812D0 - Immune direction therapy - Google Patents
Immune direction therapyInfo
- Publication number
- SE9900812D0 SE9900812D0 SE9900812A SE9900812A SE9900812D0 SE 9900812 D0 SE9900812 D0 SE 9900812D0 SE 9900812 A SE9900812 A SE 9900812A SE 9900812 A SE9900812 A SE 9900812A SE 9900812 D0 SE9900812 D0 SE 9900812D0
- Authority
- SE
- Sweden
- Prior art keywords
- immune
- host
- interleukin
- sequences
- disease
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 abstract 4
- 108090000174 Interleukin-10 Proteins 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 229940076144 interleukin-10 Drugs 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000003278 mimic effect Effects 0.000 abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002458 infectious effect Effects 0.000 abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 102000003946 Prolactin Human genes 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000003491 array Methods 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000008004 immune attack Effects 0.000 abstract 1
- 230000008102 immune modulation Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 238000011081 inoculation Methods 0.000 abstract 1
- 210000003563 lymphoid tissue Anatomy 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2518096P | 1996-09-11 | 1996-09-11 | |
PCT/IB1997/001086 WO1998010787A2 (en) | 1996-09-11 | 1997-09-10 | Pharmaceutical compositions for the treatment of immune disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
SE9900812D0 true SE9900812D0 (sv) | 1999-03-08 |
SE9900812L SE9900812L (sv) | 1999-03-08 |
Family
ID=21824510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9900812A SE9900812L (sv) | 1996-09-11 | 1999-03-08 | Riktad immunoterapi |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0929568A2 (sv) |
JP (1) | JP2001503613A (sv) |
CN (1) | CN1230195A (sv) |
AU (2) | AU6887096A (sv) |
CA (1) | CA2265885A1 (sv) |
IL (1) | IL128806A0 (sv) |
NZ (1) | NZ335039A (sv) |
SE (1) | SE9900812L (sv) |
WO (2) | WO1998010792A1 (sv) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5297299A (en) * | 1998-08-17 | 2000-03-06 | Patrick T. Prendergast | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use |
WO2000035472A2 (en) * | 1998-12-15 | 2000-06-22 | Hollis-Eden Pharmaceuticals, Inc. | Cytokine combination therapy |
EP1265634A4 (en) * | 2000-03-14 | 2005-12-28 | Nat Jewish Med & Res Center | METHOD AND COMPOSITION FOR TREATING RESPIRATORY HYPERSENSIBILITY |
FI118263B (sv) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Peptider som modulerar kaspasaktivitet |
WO2005116081A2 (en) | 2004-05-24 | 2005-12-08 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
EA008925B1 (ru) * | 2004-12-14 | 2007-08-31 | Товарищество С Ограниченной Ответственностью "Реал Мед Компани" | Способ коррекции иммунного состояния организма при сахарном диабете |
US7989590B2 (en) * | 2005-03-22 | 2011-08-02 | Rohto Pharmaceutical Co., Ltd | Peptides that increase collagen or hyaluronic acid production |
US7553932B1 (en) | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
US8283165B2 (en) | 2008-09-12 | 2012-10-09 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
US9850278B2 (en) | 2013-04-25 | 2017-12-26 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
CN103275222B (zh) * | 2013-05-15 | 2014-04-16 | 中山康方生物医药有限公司 | 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用 |
CN114163493B (zh) * | 2021-11-18 | 2023-09-15 | 浙大宁波理工学院 | 一种可作为5型磷酸二酯酶抑制剂的多肽及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0056249B1 (en) * | 1981-01-09 | 1985-06-26 | New York Blood Center, Inc. | Synthetic antigenic composition and process for making same |
US4822606A (en) * | 1986-04-07 | 1989-04-18 | Duke University | Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences |
AU1366088A (en) * | 1987-01-28 | 1988-08-24 | Ortho Pharmaceutical Corporation | Immunosuppressive peptides and methods of use |
AU620804B2 (en) * | 1987-03-23 | 1992-02-27 | Hiver Limited | Novel vaccines |
SE8705197D0 (sv) * | 1987-12-30 | 1987-12-30 | Jonas Blomberg | New peptides, two diagnostic methods using the peptides and a medicament based on the peptides |
IL97629A0 (en) * | 1990-03-26 | 1992-06-21 | Schering Corp | Bcrf1 antagonists for treating epstein-barr virus infections |
WO1993011157A1 (en) * | 1991-11-27 | 1993-06-10 | The Council Of The Queensland Institute Of Medical Research | MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX) |
ZA931489B (en) * | 1992-03-04 | 1993-10-28 | Schering Corp | Use of interleuken-10 to suppress graft-vs-host disease |
WO1993018783A1 (en) * | 1992-03-20 | 1993-09-30 | Schering Corporation | Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist |
CA2144648A1 (en) * | 1992-09-18 | 1994-03-31 | Mario Clerici | Restoration of immunocompetency to t helper cells in hiv infected patients |
NZ269766A (en) * | 1993-07-28 | 1998-01-26 | Medvet Science Pty Ltd | Haemopoietic growth factor antagonists; relates to modified forms of such factors |
DE69536065D1 (de) * | 1994-01-14 | 2010-05-27 | Rath Matthias | Hydrophile Signal-Oligopeptide und Verfahren der therapeutischen Anwendung |
AU4385696A (en) * | 1996-01-18 | 1997-08-11 | Christian Gronhoj Larsen | Synthetic il-10 analogues |
-
1996
- 1996-09-13 AU AU68870/96A patent/AU6887096A/en not_active Abandoned
- 1996-09-13 WO PCT/IB1996/000945 patent/WO1998010792A1/en active Application Filing
-
1997
- 1997-09-10 IL IL12880697A patent/IL128806A0/xx unknown
- 1997-09-10 WO PCT/IB1997/001086 patent/WO1998010787A2/en not_active Application Discontinuation
- 1997-09-10 JP JP51343598A patent/JP2001503613A/ja active Pending
- 1997-09-10 NZ NZ335039A patent/NZ335039A/en unknown
- 1997-09-10 EP EP97939105A patent/EP0929568A2/en not_active Withdrawn
- 1997-09-10 CA CA002265885A patent/CA2265885A1/en not_active Abandoned
- 1997-09-10 AU AU41320/97A patent/AU4132097A/en not_active Abandoned
- 1997-09-10 CN CN97197816A patent/CN1230195A/zh active Pending
-
1999
- 1999-03-08 SE SE9900812A patent/SE9900812L/sv not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0929568A2 (en) | 1999-07-21 |
AU4132097A (en) | 1998-04-02 |
NZ335039A (en) | 2001-04-27 |
WO1998010787A3 (en) | 1998-07-30 |
CN1230195A (zh) | 1999-09-29 |
JP2001503613A (ja) | 2001-03-21 |
AU6887096A (en) | 1998-04-02 |
IL128806A0 (en) | 2000-01-31 |
WO1998010792A1 (en) | 1998-03-19 |
WO1998010787A2 (en) | 1998-03-19 |
SE9900812L (sv) | 1999-03-08 |
CA2265885A1 (en) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9900812D0 (sv) | Immune direction therapy | |
CA2282300A1 (en) | Recombinant pox virus for immunization against muc1 tumor-associated antigen | |
GB9224584D0 (en) | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases | |
US9714272B2 (en) | Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom | |
WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
BR9710975A (pt) | Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis | |
JP2010535504A5 (sv) | ||
US20030198624A1 (en) | Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer | |
EP0913157B1 (en) | A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method | |
EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
WO2003018606A3 (en) | Casein derived peptides and uses thereof in therapy | |
JPH01104021A (ja) | 血小板第4因子のペプチドフラグメントを含む組成物及び抑制免疫応答を回復させる方法 | |
WO2004005316A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
CA2196416A1 (en) | Recombinant herpes virus with gb gene promoter | |
EP2647645A1 (en) | Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom | |
RU2076715C1 (ru) | Способ получения препарата "аффинолейкин" для противоинфекционной иммунотерапии | |
AU1156001A (en) | Recombinant therapeutic fusion proteins | |
US10822395B2 (en) | Modified anti-inflammatory proteins and method of use | |
JP5699093B2 (ja) | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 | |
WO2021231499A3 (en) | Compositions and methods for treating viral infections | |
RU2409386C1 (ru) | Вакцинный препарат | |
EP2351769A2 (en) | Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom | |
Zimecki et al. | Inhibition of interleukin 1 (IL-1)-elicited leukocytosis and LPS-induced fever by soluble immune response suppresor (SIRS) | |
Fujinamy | Virus induced disease and autoimmunity: Molecular mimicry | |
JP5004990B2 (ja) | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAV | Patent application has lapsed |
Ref document number: 9900812-0 Format of ref document f/p: F |